# Rabies:  Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/rabies-developing-monoclonal-antibody-cocktails-for-the-passive-immunization-component-of-post-exposure-prophylaxis-guidance-for-industry-draft-guidance-for-industry/6ffd0752-9587-416f-8c63-5f1ab53186bd

> FDA guidance document: Rabies:  Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry. Issue date: July 28, 2021. Get complete insights and analysis.

---

## Details

- Title: Rabies:  Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2021-07-28
- Comment Close Date: 2021-10-27
- Last Changed: 2022-02-01
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2021-D-0519">FDA-2021-D-0519</a>

## Related Documents

- [Migraine:  Developing Drugs for Preventive Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-preventive-treatment/cd739d7c-f8ed-4a37-b16f-d6f3b9550a94)
- [Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/chemotherapy-induced-nausea-and-vomiting-developing-drugs-for-prevention-guidance-for-industry-draft-guidance-for-industry/9b036fec-744d-4fca-a565-c799357b16a9)
- [Endogenous Cushing’s Syndrome: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/endogenous-cushings-syndrome-developing-drugs-for-treatment/c89a914f-8df3-4543-87dc-697dcbc10611)